nodes	percent_of_prediction	percent_of_DWPC	metapath
Halofantrine—CYP3A5—Ifosfamide—testicular cancer	0.175	0.231	CbGbCtD
Halofantrine—CYP2C8—Ifosfamide—testicular cancer	0.168	0.222	CbGbCtD
Halofantrine—CYP3A5—Etoposide—testicular cancer	0.0834	0.11	CbGbCtD
Halofantrine—CYP2C8—Etoposide—testicular cancer	0.0802	0.106	CbGbCtD
Halofantrine—CYP3A4—Ifosfamide—testicular cancer	0.068	0.09	CbGbCtD
Halofantrine—CYP2D6—Vinblastine—testicular cancer	0.0568	0.075	CbGbCtD
Halofantrine—CYP3A4—Vinblastine—testicular cancer	0.0361	0.0477	CbGbCtD
Halofantrine—CYP2D6—Doxorubicin—testicular cancer	0.0349	0.0461	CbGbCtD
Halofantrine—CYP3A4—Etoposide—testicular cancer	0.0325	0.043	CbGbCtD
Halofantrine—CYP3A4—Doxorubicin—testicular cancer	0.0222	0.0293	CbGbCtD
Halofantrine—Stomatitis—Etoposide—testicular cancer	0.00112	0.00461	CcSEcCtD
Halofantrine—Discomfort—Bleomycin—testicular cancer	0.00112	0.00461	CcSEcCtD
Halofantrine—Malaise—Dactinomycin—testicular cancer	0.00112	0.00461	CcSEcCtD
Halofantrine—Decreased appetite—Vinblastine—testicular cancer	0.00112	0.0046	CcSEcCtD
Halofantrine—Urticaria—Chlorambucil—testicular cancer	0.00112	0.00459	CcSEcCtD
Halofantrine—Abdominal pain—Chlorambucil—testicular cancer	0.00111	0.00457	CcSEcCtD
Halofantrine—Constipation—Vinblastine—testicular cancer	0.0011	0.00453	CcSEcCtD
Halofantrine—Pulmonary oedema—Methotrexate—testicular cancer	0.0011	0.00451	CcSEcCtD
Halofantrine—Confusional state—Bleomycin—testicular cancer	0.0011	0.00451	CcSEcCtD
Halofantrine—Anaphylactic shock—Bleomycin—testicular cancer	0.00109	0.00447	CcSEcCtD
Halofantrine—Visual impairment—Cisplatin—testicular cancer	0.00109	0.00447	CcSEcCtD
Halofantrine—Feeling abnormal—Vinblastine—testicular cancer	0.00106	0.00436	CcSEcCtD
Halofantrine—Myalgia—Dactinomycin—testicular cancer	0.00106	0.00435	CcSEcCtD
Halofantrine—Ill-defined disorder—Ifosfamide—testicular cancer	0.00106	0.00434	CcSEcCtD
Halofantrine—Gastrointestinal pain—Vinblastine—testicular cancer	0.00105	0.00433	CcSEcCtD
Halofantrine—Tinnitus—Cisplatin—testicular cancer	0.00105	0.00432	CcSEcCtD
Halofantrine—Discomfort—Dactinomycin—testicular cancer	0.00105	0.0043	CcSEcCtD
Halofantrine—Anorexia—Bleomycin—testicular cancer	0.00104	0.00426	CcSEcCtD
Halofantrine—Malaise—Ifosfamide—testicular cancer	0.00103	0.00422	CcSEcCtD
Halofantrine—Pulmonary oedema—Epirubicin—testicular cancer	0.00103	0.00422	CcSEcCtD
Halofantrine—Abdominal pain—Vinblastine—testicular cancer	0.00102	0.00419	CcSEcCtD
Halofantrine—Asthenia—Chlorambucil—testicular cancer	0.00101	0.00415	CcSEcCtD
Halofantrine—Arrhythmia—Cisplatin—testicular cancer	0.00101	0.00414	CcSEcCtD
Halofantrine—Palpitations—Ifosfamide—testicular cancer	0.00101	0.00414	CcSEcCtD
Halofantrine—Abnormal vision—Epirubicin—testicular cancer	0.00101	0.00414	CcSEcCtD
Halofantrine—Pruritus—Chlorambucil—testicular cancer	0.000996	0.00409	CcSEcCtD
Halofantrine—Cough—Ifosfamide—testicular cancer	0.000995	0.00409	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000992	0.00407	CcSEcCtD
Halofantrine—Convulsion—Ifosfamide—testicular cancer	0.000988	0.00406	CcSEcCtD
Halofantrine—Paraesthesia—Bleomycin—testicular cancer	0.000978	0.00402	CcSEcCtD
Halofantrine—Arthralgia—Ifosfamide—testicular cancer	0.000971	0.00399	CcSEcCtD
Halofantrine—Myalgia—Ifosfamide—testicular cancer	0.000971	0.00399	CcSEcCtD
Halofantrine—Chest pain—Ifosfamide—testicular cancer	0.000971	0.00399	CcSEcCtD
Halofantrine—Anorexia—Dactinomycin—testicular cancer	0.000968	0.00398	CcSEcCtD
Halofantrine—Diarrhoea—Chlorambucil—testicular cancer	0.000963	0.00395	CcSEcCtD
Halofantrine—Discomfort—Ifosfamide—testicular cancer	0.000959	0.00394	CcSEcCtD
Halofantrine—Pulmonary oedema—Doxorubicin—testicular cancer	0.000951	0.00391	CcSEcCtD
Halofantrine—Decreased appetite—Bleomycin—testicular cancer	0.000947	0.00389	CcSEcCtD
Halofantrine—Confusional state—Ifosfamide—testicular cancer	0.000938	0.00385	CcSEcCtD
Halofantrine—Abnormal vision—Doxorubicin—testicular cancer	0.000932	0.00383	CcSEcCtD
Halofantrine—Anaphylactic shock—Ifosfamide—testicular cancer	0.000931	0.00382	CcSEcCtD
Halofantrine—Chills—Etoposide—testicular cancer	0.000928	0.00381	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000925	0.0038	CcSEcCtD
Halofantrine—Asthenia—Vinblastine—testicular cancer	0.000925	0.0038	CcSEcCtD
Halofantrine—Cerebrovascular accident—Methotrexate—testicular cancer	0.000914	0.00375	CcSEcCtD
Halofantrine—Ill-defined disorder—Cisplatin—testicular cancer	0.000912	0.00375	CcSEcCtD
Halofantrine—Feeling abnormal—Bleomycin—testicular cancer	0.000897	0.00368	CcSEcCtD
Halofantrine—Vomiting—Chlorambucil—testicular cancer	0.000895	0.00367	CcSEcCtD
Halofantrine—Anorexia—Ifosfamide—testicular cancer	0.000887	0.00364	CcSEcCtD
Halofantrine—Malaise—Cisplatin—testicular cancer	0.000887	0.00364	CcSEcCtD
Halofantrine—Decreased appetite—Dactinomycin—testicular cancer	0.000883	0.00363	CcSEcCtD
Halofantrine—Diarrhoea—Vinblastine—testicular cancer	0.000882	0.00362	CcSEcCtD
Halofantrine—Fatigue—Dactinomycin—testicular cancer	0.000876	0.0036	CcSEcCtD
Halofantrine—Back pain—Etoposide—testicular cancer	0.000871	0.00358	CcSEcCtD
Halofantrine—Urticaria—Bleomycin—testicular cancer	0.000865	0.00355	CcSEcCtD
Halofantrine—Cerebrovascular accident—Epirubicin—testicular cancer	0.000856	0.00351	CcSEcCtD
Halofantrine—Dizziness—Vinblastine—testicular cancer	0.000853	0.0035	CcSEcCtD
Halofantrine—Convulsion—Cisplatin—testicular cancer	0.000852	0.0035	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000848	0.00348	CcSEcCtD
Halofantrine—Myalgia—Cisplatin—testicular cancer	0.000837	0.00344	CcSEcCtD
Halofantrine—Feeling abnormal—Dactinomycin—testicular cancer	0.000837	0.00344	CcSEcCtD
Halofantrine—Nausea—Chlorambucil—testicular cancer	0.000836	0.00343	CcSEcCtD
Halofantrine—Paraesthesia—Ifosfamide—testicular cancer	0.000836	0.00343	CcSEcCtD
Halofantrine—Ill-defined disorder—Etoposide—testicular cancer	0.000836	0.00343	CcSEcCtD
Halofantrine—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000831	0.00341	CcSEcCtD
Halofantrine—Discomfort—Cisplatin—testicular cancer	0.000827	0.0034	CcSEcCtD
Halofantrine—Vomiting—Vinblastine—testicular cancer	0.00082	0.00337	CcSEcCtD
Halofantrine—Malaise—Etoposide—testicular cancer	0.000812	0.00333	CcSEcCtD
Halofantrine—Face oedema—Epirubicin—testicular cancer	0.000809	0.00332	CcSEcCtD
Halofantrine—Decreased appetite—Ifosfamide—testicular cancer	0.000809	0.00332	CcSEcCtD
Halofantrine—Headache—Vinblastine—testicular cancer	0.000808	0.00332	CcSEcCtD
Halofantrine—Abdominal pain—Dactinomycin—testicular cancer	0.000803	0.0033	CcSEcCtD
Halofantrine—Fatigue—Ifosfamide—testicular cancer	0.000802	0.00329	CcSEcCtD
Halofantrine—Anaphylactic shock—Cisplatin—testicular cancer	0.000802	0.00329	CcSEcCtD
Halofantrine—Constipation—Ifosfamide—testicular cancer	0.000796	0.00327	CcSEcCtD
Halofantrine—Cerebrovascular accident—Doxorubicin—testicular cancer	0.000792	0.00325	CcSEcCtD
Halofantrine—Cough—Etoposide—testicular cancer	0.000786	0.00323	CcSEcCtD
Halofantrine—Asthenia—Bleomycin—testicular cancer	0.000781	0.00321	CcSEcCtD
Halofantrine—Convulsion—Etoposide—testicular cancer	0.00078	0.0032	CcSEcCtD
Halofantrine—Pruritus—Bleomycin—testicular cancer	0.000771	0.00316	CcSEcCtD
Halofantrine—Feeling abnormal—Ifosfamide—testicular cancer	0.000767	0.00315	CcSEcCtD
Halofantrine—Chest pain—Etoposide—testicular cancer	0.000767	0.00315	CcSEcCtD
Halofantrine—Nausea—Vinblastine—testicular cancer	0.000766	0.00314	CcSEcCtD
Halofantrine—Orthostatic hypotension—Epirubicin—testicular cancer	0.000766	0.00314	CcSEcCtD
Halofantrine—Anorexia—Cisplatin—testicular cancer	0.000765	0.00314	CcSEcCtD
Halofantrine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000761	0.00312	CcSEcCtD
Halofantrine—Discomfort—Etoposide—testicular cancer	0.000758	0.00311	CcSEcCtD
Halofantrine—Face oedema—Doxorubicin—testicular cancer	0.000749	0.00307	CcSEcCtD
Halofantrine—Confusional state—Etoposide—testicular cancer	0.000741	0.00304	CcSEcCtD
Halofantrine—Urticaria—Ifosfamide—testicular cancer	0.000739	0.00304	CcSEcCtD
Halofantrine—Abdominal pain—Ifosfamide—testicular cancer	0.000736	0.00302	CcSEcCtD
Halofantrine—Anaphylactic shock—Etoposide—testicular cancer	0.000735	0.00302	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000731	0.003	CcSEcCtD
Halofantrine—Abdominal distension—Epirubicin—testicular cancer	0.000729	0.003	CcSEcCtD
Halofantrine—Asthenia—Dactinomycin—testicular cancer	0.000729	0.00299	CcSEcCtD
Halofantrine—Paraesthesia—Cisplatin—testicular cancer	0.000721	0.00296	CcSEcCtD
Halofantrine—Orthostatic hypotension—Doxorubicin—testicular cancer	0.000709	0.00291	CcSEcCtD
Halofantrine—Anorexia—Etoposide—testicular cancer	0.000701	0.00288	CcSEcCtD
Halofantrine—Decreased appetite—Cisplatin—testicular cancer	0.000698	0.00286	CcSEcCtD
Halofantrine—Diarrhoea—Dactinomycin—testicular cancer	0.000695	0.00285	CcSEcCtD
Halofantrine—Vomiting—Bleomycin—testicular cancer	0.000692	0.00284	CcSEcCtD
Halofantrine—Rash—Bleomycin—testicular cancer	0.000687	0.00282	CcSEcCtD
Halofantrine—Dermatitis—Bleomycin—testicular cancer	0.000686	0.00282	CcSEcCtD
Halofantrine—Abdominal distension—Doxorubicin—testicular cancer	0.000675	0.00277	CcSEcCtD
Halofantrine—Stomatitis—Methotrexate—testicular cancer	0.000673	0.00276	CcSEcCtD
Halofantrine—Pollakiuria—Epirubicin—testicular cancer	0.000669	0.00275	CcSEcCtD
Halofantrine—Asthenia—Ifosfamide—testicular cancer	0.000668	0.00274	CcSEcCtD
Halofantrine—Feeling abnormal—Cisplatin—testicular cancer	0.000661	0.00271	CcSEcCtD
Halofantrine—Paraesthesia—Etoposide—testicular cancer	0.00066	0.00271	CcSEcCtD
Halofantrine—Pruritus—Ifosfamide—testicular cancer	0.000659	0.0027	CcSEcCtD
Halofantrine—Nausea—Bleomycin—testicular cancer	0.000647	0.00266	CcSEcCtD
Halofantrine—Vomiting—Dactinomycin—testicular cancer	0.000646	0.00265	CcSEcCtD
Halofantrine—Rash—Dactinomycin—testicular cancer	0.00064	0.00263	CcSEcCtD
Halofantrine—Decreased appetite—Etoposide—testicular cancer	0.000639	0.00262	CcSEcCtD
Halofantrine—Diarrhoea—Ifosfamide—testicular cancer	0.000637	0.00261	CcSEcCtD
Halofantrine—Fatigue—Etoposide—testicular cancer	0.000634	0.0026	CcSEcCtD
Halofantrine—Stomatitis—Epirubicin—testicular cancer	0.00063	0.00259	CcSEcCtD
Halofantrine—Constipation—Etoposide—testicular cancer	0.000629	0.00258	CcSEcCtD
Halofantrine—Pollakiuria—Doxorubicin—testicular cancer	0.000619	0.00254	CcSEcCtD
Halofantrine—Dizziness—Ifosfamide—testicular cancer	0.000615	0.00253	CcSEcCtD
Halofantrine—Feeling abnormal—Etoposide—testicular cancer	0.000606	0.00249	CcSEcCtD
Halofantrine—Nausea—Dactinomycin—testicular cancer	0.000603	0.00248	CcSEcCtD
Halofantrine—Gastrointestinal pain—Etoposide—testicular cancer	0.000601	0.00247	CcSEcCtD
Halofantrine—Visual impairment—Methotrexate—testicular cancer	0.000597	0.00245	CcSEcCtD
Halofantrine—Vomiting—Ifosfamide—testicular cancer	0.000592	0.00243	CcSEcCtD
Halofantrine—Rash—Ifosfamide—testicular cancer	0.000587	0.00241	CcSEcCtD
Halofantrine—Dermatitis—Ifosfamide—testicular cancer	0.000586	0.00241	CcSEcCtD
Halofantrine—Urticaria—Etoposide—testicular cancer	0.000584	0.0024	CcSEcCtD
Halofantrine—Stomatitis—Doxorubicin—testicular cancer	0.000583	0.00239	CcSEcCtD
Halofantrine—Abdominal pain—Etoposide—testicular cancer	0.000581	0.00239	CcSEcCtD
Halofantrine—Tinnitus—Methotrexate—testicular cancer	0.000578	0.00237	CcSEcCtD
Halofantrine—Asthenia—Cisplatin—testicular cancer	0.000576	0.00236	CcSEcCtD
Halofantrine—Visual impairment—Epirubicin—testicular cancer	0.000559	0.00229	CcSEcCtD
Halofantrine—Chills—Methotrexate—testicular cancer	0.000556	0.00228	CcSEcCtD
Halofantrine—Nausea—Ifosfamide—testicular cancer	0.000553	0.00227	CcSEcCtD
Halofantrine—Diarrhoea—Cisplatin—testicular cancer	0.000549	0.00225	CcSEcCtD
Halofantrine—Tinnitus—Epirubicin—testicular cancer	0.000541	0.00222	CcSEcCtD
Halofantrine—Asthenia—Etoposide—testicular cancer	0.000527	0.00217	CcSEcCtD
Halofantrine—Back pain—Methotrexate—testicular cancer	0.000522	0.00214	CcSEcCtD
Halofantrine—Chills—Epirubicin—testicular cancer	0.00052	0.00214	CcSEcCtD
Halofantrine—Pruritus—Etoposide—testicular cancer	0.00052	0.00214	CcSEcCtD
Halofantrine—Arrhythmia—Epirubicin—testicular cancer	0.000518	0.00213	CcSEcCtD
Halofantrine—Visual impairment—Doxorubicin—testicular cancer	0.000517	0.00212	CcSEcCtD
Halofantrine—Vomiting—Cisplatin—testicular cancer	0.00051	0.00209	CcSEcCtD
Halofantrine—Rash—Cisplatin—testicular cancer	0.000506	0.00208	CcSEcCtD
Halofantrine—Dermatitis—Cisplatin—testicular cancer	0.000505	0.00208	CcSEcCtD
Halofantrine—Diarrhoea—Etoposide—testicular cancer	0.000503	0.00207	CcSEcCtD
Halofantrine—Ill-defined disorder—Methotrexate—testicular cancer	0.000501	0.00206	CcSEcCtD
Halofantrine—Tinnitus—Doxorubicin—testicular cancer	0.0005	0.00205	CcSEcCtD
Halofantrine—Back pain—Epirubicin—testicular cancer	0.000488	0.00201	CcSEcCtD
Halofantrine—Malaise—Methotrexate—testicular cancer	0.000487	0.002	CcSEcCtD
Halofantrine—Dizziness—Etoposide—testicular cancer	0.000486	0.002	CcSEcCtD
Halofantrine—Chills—Doxorubicin—testicular cancer	0.000482	0.00198	CcSEcCtD
Halofantrine—Arrhythmia—Doxorubicin—testicular cancer	0.000479	0.00197	CcSEcCtD
Halofantrine—Nausea—Cisplatin—testicular cancer	0.000477	0.00196	CcSEcCtD
Halofantrine—Cough—Methotrexate—testicular cancer	0.000471	0.00193	CcSEcCtD
Halofantrine—Ill-defined disorder—Epirubicin—testicular cancer	0.000468	0.00192	CcSEcCtD
Halofantrine—Convulsion—Methotrexate—testicular cancer	0.000467	0.00192	CcSEcCtD
Halofantrine—Vomiting—Etoposide—testicular cancer	0.000467	0.00192	CcSEcCtD
Halofantrine—Rash—Etoposide—testicular cancer	0.000463	0.0019	CcSEcCtD
Halofantrine—Dermatitis—Etoposide—testicular cancer	0.000463	0.0019	CcSEcCtD
Halofantrine—Headache—Etoposide—testicular cancer	0.000461	0.00189	CcSEcCtD
Halofantrine—Arthralgia—Methotrexate—testicular cancer	0.000459	0.00189	CcSEcCtD
Halofantrine—Chest pain—Methotrexate—testicular cancer	0.000459	0.00189	CcSEcCtD
Halofantrine—Myalgia—Methotrexate—testicular cancer	0.000459	0.00189	CcSEcCtD
Halofantrine—Malaise—Epirubicin—testicular cancer	0.000455	0.00187	CcSEcCtD
Halofantrine—Discomfort—Methotrexate—testicular cancer	0.000454	0.00186	CcSEcCtD
Halofantrine—Back pain—Doxorubicin—testicular cancer	0.000452	0.00186	CcSEcCtD
Halofantrine—Palpitations—Epirubicin—testicular cancer	0.000446	0.00183	CcSEcCtD
Halofantrine—Confusional state—Methotrexate—testicular cancer	0.000444	0.00182	CcSEcCtD
Halofantrine—Cough—Epirubicin—testicular cancer	0.000441	0.00181	CcSEcCtD
Halofantrine—Anaphylactic shock—Methotrexate—testicular cancer	0.00044	0.00181	CcSEcCtD
Halofantrine—Convulsion—Epirubicin—testicular cancer	0.000437	0.0018	CcSEcCtD
Halofantrine—Nausea—Etoposide—testicular cancer	0.000437	0.00179	CcSEcCtD
Halofantrine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000433	0.00178	CcSEcCtD
Halofantrine—Arthralgia—Epirubicin—testicular cancer	0.00043	0.00176	CcSEcCtD
Halofantrine—Myalgia—Epirubicin—testicular cancer	0.00043	0.00176	CcSEcCtD
Halofantrine—Chest pain—Epirubicin—testicular cancer	0.00043	0.00176	CcSEcCtD
Halofantrine—Discomfort—Epirubicin—testicular cancer	0.000425	0.00174	CcSEcCtD
Halofantrine—Malaise—Doxorubicin—testicular cancer	0.000421	0.00173	CcSEcCtD
Halofantrine—Anorexia—Methotrexate—testicular cancer	0.00042	0.00172	CcSEcCtD
Halofantrine—Confusional state—Epirubicin—testicular cancer	0.000415	0.00171	CcSEcCtD
Halofantrine—Palpitations—Doxorubicin—testicular cancer	0.000413	0.0017	CcSEcCtD
Halofantrine—Anaphylactic shock—Epirubicin—testicular cancer	0.000412	0.00169	CcSEcCtD
Halofantrine—Cough—Doxorubicin—testicular cancer	0.000408	0.00167	CcSEcCtD
Halofantrine—Convulsion—Doxorubicin—testicular cancer	0.000405	0.00166	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000401	0.00165	CcSEcCtD
Halofantrine—Arthralgia—Doxorubicin—testicular cancer	0.000398	0.00163	CcSEcCtD
Halofantrine—Myalgia—Doxorubicin—testicular cancer	0.000398	0.00163	CcSEcCtD
Halofantrine—Chest pain—Doxorubicin—testicular cancer	0.000398	0.00163	CcSEcCtD
Halofantrine—Paraesthesia—Methotrexate—testicular cancer	0.000395	0.00162	CcSEcCtD
Halofantrine—Discomfort—Doxorubicin—testicular cancer	0.000393	0.00161	CcSEcCtD
Halofantrine—Anorexia—Epirubicin—testicular cancer	0.000393	0.00161	CcSEcCtD
Halofantrine—Dyspepsia—Methotrexate—testicular cancer	0.000388	0.00159	CcSEcCtD
Halofantrine—Confusional state—Doxorubicin—testicular cancer	0.000384	0.00158	CcSEcCtD
Halofantrine—Decreased appetite—Methotrexate—testicular cancer	0.000383	0.00157	CcSEcCtD
Halofantrine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000381	0.00157	CcSEcCtD
Halofantrine—Fatigue—Methotrexate—testicular cancer	0.00038	0.00156	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000375	0.00154	CcSEcCtD
Halofantrine—Paraesthesia—Epirubicin—testicular cancer	0.00037	0.00152	CcSEcCtD
Halofantrine—Anorexia—Doxorubicin—testicular cancer	0.000363	0.00149	CcSEcCtD
Halofantrine—Feeling abnormal—Methotrexate—testicular cancer	0.000363	0.00149	CcSEcCtD
Halofantrine—Dyspepsia—Epirubicin—testicular cancer	0.000363	0.00149	CcSEcCtD
Halofantrine—Gastrointestinal pain—Methotrexate—testicular cancer	0.00036	0.00148	CcSEcCtD
Halofantrine—Decreased appetite—Epirubicin—testicular cancer	0.000358	0.00147	CcSEcCtD
Halofantrine—Fatigue—Epirubicin—testicular cancer	0.000355	0.00146	CcSEcCtD
Halofantrine—Constipation—Epirubicin—testicular cancer	0.000352	0.00145	CcSEcCtD
Halofantrine—Urticaria—Methotrexate—testicular cancer	0.00035	0.00144	CcSEcCtD
Halofantrine—Abdominal pain—Methotrexate—testicular cancer	0.000348	0.00143	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000347	0.00143	CcSEcCtD
Halofantrine—Paraesthesia—Doxorubicin—testicular cancer	0.000342	0.00141	CcSEcCtD
Halofantrine—Feeling abnormal—Epirubicin—testicular cancer	0.00034	0.00139	CcSEcCtD
Halofantrine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000337	0.00138	CcSEcCtD
Halofantrine—Dyspepsia—Doxorubicin—testicular cancer	0.000336	0.00138	CcSEcCtD
Halofantrine—Decreased appetite—Doxorubicin—testicular cancer	0.000331	0.00136	CcSEcCtD
Halofantrine—Fatigue—Doxorubicin—testicular cancer	0.000329	0.00135	CcSEcCtD
Halofantrine—Urticaria—Epirubicin—testicular cancer	0.000327	0.00134	CcSEcCtD
Halofantrine—Constipation—Doxorubicin—testicular cancer	0.000326	0.00134	CcSEcCtD
Halofantrine—Abdominal pain—Epirubicin—testicular cancer	0.000326	0.00134	CcSEcCtD
Halofantrine—Asthenia—Methotrexate—testicular cancer	0.000316	0.0013	CcSEcCtD
Halofantrine—Feeling abnormal—Doxorubicin—testicular cancer	0.000314	0.00129	CcSEcCtD
Halofantrine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000312	0.00128	CcSEcCtD
Halofantrine—Pruritus—Methotrexate—testicular cancer	0.000312	0.00128	CcSEcCtD
Halofantrine—Urticaria—Doxorubicin—testicular cancer	0.000303	0.00124	CcSEcCtD
Halofantrine—Abdominal pain—Doxorubicin—testicular cancer	0.000301	0.00124	CcSEcCtD
Halofantrine—Diarrhoea—Methotrexate—testicular cancer	0.000301	0.00124	CcSEcCtD
Halofantrine—Asthenia—Epirubicin—testicular cancer	0.000296	0.00121	CcSEcCtD
Halofantrine—Pruritus—Epirubicin—testicular cancer	0.000292	0.0012	CcSEcCtD
Halofantrine—Dizziness—Methotrexate—testicular cancer	0.000291	0.0012	CcSEcCtD
Halofantrine—Diarrhoea—Epirubicin—testicular cancer	0.000282	0.00116	CcSEcCtD
Halofantrine—Vomiting—Methotrexate—testicular cancer	0.00028	0.00115	CcSEcCtD
Halofantrine—Rash—Methotrexate—testicular cancer	0.000278	0.00114	CcSEcCtD
Halofantrine—Dermatitis—Methotrexate—testicular cancer	0.000277	0.00114	CcSEcCtD
Halofantrine—Headache—Methotrexate—testicular cancer	0.000276	0.00113	CcSEcCtD
Halofantrine—Asthenia—Doxorubicin—testicular cancer	0.000274	0.00112	CcSEcCtD
Halofantrine—Dizziness—Epirubicin—testicular cancer	0.000272	0.00112	CcSEcCtD
Halofantrine—Pruritus—Doxorubicin—testicular cancer	0.00027	0.00111	CcSEcCtD
Halofantrine—Vomiting—Epirubicin—testicular cancer	0.000262	0.00108	CcSEcCtD
Halofantrine—Nausea—Methotrexate—testicular cancer	0.000262	0.00107	CcSEcCtD
Halofantrine—Diarrhoea—Doxorubicin—testicular cancer	0.000261	0.00107	CcSEcCtD
Halofantrine—Rash—Epirubicin—testicular cancer	0.00026	0.00107	CcSEcCtD
Halofantrine—Dermatitis—Epirubicin—testicular cancer	0.00026	0.00107	CcSEcCtD
Halofantrine—Headache—Epirubicin—testicular cancer	0.000258	0.00106	CcSEcCtD
Halofantrine—Dizziness—Doxorubicin—testicular cancer	0.000252	0.00104	CcSEcCtD
Halofantrine—Nausea—Epirubicin—testicular cancer	0.000245	0.001	CcSEcCtD
Halofantrine—Vomiting—Doxorubicin—testicular cancer	0.000242	0.000995	CcSEcCtD
Halofantrine—Rash—Doxorubicin—testicular cancer	0.00024	0.000987	CcSEcCtD
Halofantrine—Dermatitis—Doxorubicin—testicular cancer	0.00024	0.000986	CcSEcCtD
Halofantrine—Headache—Doxorubicin—testicular cancer	0.000239	0.000981	CcSEcCtD
Halofantrine—Nausea—Doxorubicin—testicular cancer	0.000226	0.00093	CcSEcCtD
